Effects of Hardaliye, a Fermented Grape Drink, on Oxidative Stress, Lipid Profile and Blood Pressure in Young Footballers

Sponsor
Medipol University (Other)
Overall Status
Completed
CT.gov ID
NCT05722600
Collaborator
(none)
36
1
2
1.1
31.3

Study Details

Study Description

Brief Summary

In the present study, the authors aimed to investigate the effects of hardaliye (grape juice) consumption on oxidative stress parameters, lipid profile and blood pressure in young football players.

Condition or Disease Intervention/Treatment Phase
  • Other: Grape juice
  • Other: Placebo drink
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Supportive Care
Official Title:
Effects of Hardaliye, a Fermented Grape Drink, on Oxidative Stress, Lipid Profile and Blood Pressure in Young Footballers: A Randomised Trial
Actual Study Start Date :
Feb 1, 2022
Actual Primary Completion Date :
Mar 8, 2022
Actual Study Completion Date :
Mar 8, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Hardaliye Group

Hardaliye Group consumed 250 ml/day of hardaliye (grape juice) for 28 days.

Other: Grape juice
Hardaliye (grape juice) is a fermented, traditional non-alcoholic beverage made from fresh grapes. It is mainly produced by the fermentation of grapes, sour cherry leaves and mustard seeds. Hardaliye was purchased from traditional producers in Turkey. Hardaliye Group consumed 250 ml/day of hardaliye (grape juice) for 28 days.

Placebo Comparator: Placebo Group

Placebo Group consumed 250 ml/day of placebo drink for 28 days.

Other: Placebo drink
Placebo drink has carbohydrate, energy and sensory properties similar to hardaliye. Placebo Group consumed 250 ml/day of placebo drink

Outcome Measures

Primary Outcome Measures

  1. Change in total antioxidant capacity [28 days]

    Measurement of serum level of total antioxidant capacity (μmol Trolox eq/L).

  2. Change in total oxidation status [28 days]

    Measurement of serum level of total oxidation status (μmol H2O2 eq/L).

  3. Change in oxidative stress index [28 days]

    (Serum level of total oxidation status/serum level of total antioxidant capacity) × 100

  4. Change in lipid parameters [28 days]

    Measurement of serum levels total cholesterol (mg/dl), HDL-cholesterol (mg/dl), LDL-cholesterol (mg/dl) and triglycerides (mg/dl).

  5. Change in blood pressure [28 days]

    Measurement of systolic (mm Hg) and diastolic blood pressure (mm Hg)

Secondary Outcome Measures

  1. Change in perceived exercise-induced pain [28 days]

    Perceived exercise-induced pain was determined using the 100-mm Visual Analog Scale. 100-mm Visual Analog Scale scores range from 0 (no pain) to 100 (most severe pain). A higher score indicates a higher perceived pain level.

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 24 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Being a male football player playing in a team in the Elite Development League,

  • Participating in training with the team at least 5 days a week for 3 months,

  • Not consuming red wine, grape juice, and/or hardaliye regularly before the study was started,

  • Those who stayed in the sports facility where catering service was provided for breakfast, lunch and dinner were included in the study.

Exclusion Criteria:
  • With chronic disease,

  • Smoker,

  • Those taking antioxidant supplements,

  • Non-cooperative subjects or unwilling to sign an informed consent and participate in the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Istanbul Medipol University İstanbul Turkey

Sponsors and Collaborators

  • Medipol University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ramazan Mert Atan, Principal Investigator, Medipol University
ClinicalTrials.gov Identifier:
NCT05722600
Other Study ID Numbers:
  • RMAtan
First Posted:
Feb 10, 2023
Last Update Posted:
Feb 10, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Feb 10, 2023